LifeSci Communications Fierce Pharma Asia—Takeda's Anima mRNA translation pact, China digital health incubator; Daiichi's COVID-19 vaccine

Takeda penned a potentially billion-dollar deal with Anima Biotech to work on mRNA translation modulators for neurological diseases. The Japanese pharma als

Anima Biotech - mRNA Lightning Platform

Daiichi Sankyo: Drugmaker roars back to health with cancer success - Nikkei Asia

COVID-19 tracker: Pfizer, Moderna vaccines sharply cut hospitalizations in older adults, CDC data show

AbbVie to Develop mRNA Modulators Using Anima Biotech Platform

BioSpectrum Asia Jan 2023 - Flip eBook Pages 1-50

JCI - Article_in_issue

Coronavirus tracker: Sinovac unveils midstage vaccine data; Daewoong OK'd to test tapeworm med against virus

Japan's Daiichi Sankyo to make mRNA vaccine pillar of business - Nikkei Asia

Chinese COVID-19 vaccine Ad5-Ncov shows high antibody levels at Russian trial -Ifax

Japan's Daiichi Sankyo to seek OK for omicron booster by April 2024 - Nikkei Asia

Anima Biotech - mRNA Lightning Platform

Sponsor Detail Template – Chinese American Biopharmaceutical Society

Unlocking The Power of mRNA Vaccines and Therapies